They talk about us
Starpax Biopharma Never-Before-Seen Magnetodrones™ and PolarTrak® Technology Transform Cancer Treatment
Starpax Biopharma is preparing to start clinical trials this year with its patented Starpax cancer treatment platform across six unmet needs, including pancreatic, breast, colorectal, head & neck, uterus and prostate cancer. Solid cancers like the ones Starpax will focus on in the upcoming trials account for 89% of all cancer deaths – that’s largely due to the fact that solid tumors are so difficult to treat…
Benzinga – September 27, 2023
After Achieving 100% Cancer Remission Rates In Preclinical Studies, Starpax Magnetodrones Head For Human Trials
MONTREAL, June 25, 2024 /PRNewswire/ — In a significant stride for cancer treatment, Starpax Biopharma Inc. (“Starpax”) today unveiled its Starpax Cancer Treatment Platform™, a groundbreaking innovation that marks a monumental achievement in the company’s journey towards pioneering new frontiers in cancer treatment. With a 100% remission rate and no meaningful side effects in all the subjects of the company’s preclinical trials, this technology is conceived to address all solid tumors, representing 90% of cancer and 89% of deaths…
PR Newswire – September 27, 2023
STARPAX BIOPHARMA ANNOUNCES LAUNCH OF $24 MILLION REGULATION A+ CAPITAL RAISE
Starpax Biopharma Inc., a biopharmaceutical company developing a groundbreaking cancer treatment platform technology, is pleased to announce the launch of its Regulation A+ capital raise. This raise will provide an opportunity for US accredited and non-accredited investors to participate in the company’s mission to revolutionize cancer treatment…
Benzinga – August 18th 2023
Michael GAREAU Interview
Starpax Biopharma Inc. has developed a novel Precision 3D Guidance Therapy of Magnetodrones™ in tumors. Magnetodrones™ are unique medication-bearing bacteria, developed by Starpax™, that are sensitive to magnetic fields. They deliver the medication into the tumor’s mass, without allowing it to circulate in the bloodstream. At the same time, the Magnetodrones™ saturate hypoxic areas where cancerous cells are difficult to reach with other treatments. Magnetodrones are injected directly into the tumor and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak™ prevents the Magnetodrones™ from leaving the tumor and guides them in 3D with special magnetic fields.
The Jewish General Hospital – July 24, 2022
Bacteria against cancer
In the basement of the Jewish General Hospital, a small room formerly used for radiation oncology now houses an imposing machine, known as the PolarTrak. This is where patients will test a completely new cancer treatment therapy starting in 2023.
Top Therapeutic Solution which is at the forefront of addressing unmet treatment challenges
Life Sciences ReviewJune 12 2023
In the ever-evolving world of biopharmaceuticals, one name stands out as a beacon of innovation and leadership: Michael Gareau. As the President & CEO, and Chairman of Starpax Biopharma Inc., a company he established in 2017, Gareau has charted an impressive path marked by remarkable achievements…
Polytechnique Montréal – March 24, 2023
From discovery to impact
He says chemotherapy drugs for more than a century have been injected in the bloodstream, so less than 1 per cent of the dose reaches the tumour while the rest of the toxic molecules spread throughout the body. “A meta-analysis of 117 studies around the world concluded that 90 per cent of the volume of a tumour receives little or no drug at all at all with systemic chemotherapy,” Mr. Gareau notes…
Top Therapeutic Solution which is at the forefront of addressing unmet treatment challenges
Life Sciences ReviewAugust 1, 2022
Life Sciences Review – August 1, 2022
Starpax Magnetodrones™ : Propel cancer medicine into the future.
The 21st-century medical science has touched the acme of success.
From the human genome draft to nanomedicine, then Magnetodrones™, incredible medical breakthroughs have completely changed the way conditions and diseases are treated. Amidst all these achievements, one factor that continues to torment medicine researchers in cancer, which oncologist Dr. Siddhartha Mukherjee in his Pulitzer-winning book, refers to as “The Emporor of All Maladies.” And rightly so, in the next five years, according to reports, cancer is estimated to kill more than 50 million people…
